Q4 Biotech Playbook: Buy the Washout, Front-Run BBIO, SVRA

Two things happen in biotech every fourth quarter that nobody on the conference calls talks about. First, tax-loss selling crushes the year’s losers into late December, and the January bounce is one of the most reliable patterns in the sector. The mechanics are simple: investors who took gains elsewhere realize their losers before year-end to offset the tax bill, and the selling is concentrated in the names that already collapsed, which is exactly where the January reversal is largest. Second, the Q4 PDUFA calendar is stacked with binary catalysts that can double a beaten-down stock regardless of the seasonal selling. The playbook is simple: identify the names that get washed out in December, buy them into the tax-loss selling, front-run the top Q4 catalysts, and do nothing for the first two weeks of January. Here is the full plan, priced off the September 3 close.

The tax-loss washout list

These four names have been destroyed in 2026 and will be sold into year-end for tax purposes by December. Each has a catalyst in early 2027 that could re-rate it in January, which is exactly the setup the January effect feeds on. The XBI is up 38% on the year, so the selling is not indiscriminate; it concentrates in the specific failures, and that is what makes the washout names tradeable.

Capricor (CAPR, $9.28, $570 million market cap). Deramiocel’s Duchenne cardiomyopathy AdCom voted 9-3 against it in July, and the stock fell from $19.83 to below $4 before recovering. The FDA extended the PDUFA to November 22 for an upper-limb-only claim, and Oppenheimer upgraded it in August. It is down more than half from its pre-AdCom level and carries a November binary, which makes it a washout name with a near-term catalyst rather than a pure January play. See the Capricor deramiocel AdCom coverage.

Gossamer Bio (GOSS, $0.18, $82 million market cap). Seralutinib missed its Phase 3 PROSERA primary endpoint in February, the stock is down 77% from its pre-data level, and management is filing an NDA anyway on a “review issue, not a filing issue” theory. At $0.18 this is a cash-value lottery ticket and the purest January-effect name of the four: no one holds a penny stock into year-end out of pride, they hold it for the tax loss. See the Gossamer failure note.

Tenax (TENX, $1.78, $70 million market cap). TNX-103 missed the Phase 3 LEVEL primary endpoint cleanly (a 3.5-meter walk gap, p=0.63) and the stock lost 90% of its value intraday. Its only asset failed, and the company is asking the FDA for a protocol reboot. This is a zero-or-reboot binary with no near-term data catalyst, which makes it the riskiest name on the list. See the Tenax failure note.

Innate Pharma (IPHA, $2.11, $240 million market cap). The Sobi deal for lacutamab delivered $75 million upfront in August and validated the KIR3DL2 target, but the confirmatory Phase 3 has not started and the ADR trades on thin volume. It is a micro-cap that will get sold for tax losses into December, with the TELLOMAK-3 start as the 2027 catalyst. See the Sobi deal coverage.

The Q4 PDUFAs ranked by risk-reward

The calendar is dense. These are ranked by conviction, not by date. The month-by-month breakdowns are in the October, November, and December roundups.

1. BBIO BBP-418 (November 27, LGMD2i). BridgeBio at $75.41 and a $14.96 billion market cap. This is the highest-conviction binary on the calendar: a rare disease drug with clean Phase 3 data and a well-understood approval pathway. An approval re-rates the stock by double digits rather than a rounding error. See the BBP-418 LGMD2i primer.

2. SVRA MOLBREEVI (November 22, aPAP). Savara at $5.37 and a $1.12 billion market cap. The IMPALA-2 trial data supports approval, the drug would be the first therapy for autoimmune pulmonary alveolar proteinosis, and at $1.12 billion the market is not yet pricing a full approval plus launch. See the MOLBREEVI primer.

3. COGT bezuclastinib (November 30 GIST with sunitinib; December 30 non-advanced systemic mastocytosis). Cogent at $34.95 and a $6 billion market cap. Two PDUFAs six weeks apart is rare double-binary risk. The GIST filing is the cleaner approval; the mastocytosis filing is the larger commercial market. See the GIST primer and NonAdvSM primer.

4. IONS/GSK bepirovirsen (October 26, HBV functional cure). Ionis at $58.13 and a $10.19 billion market cap. The B-Well trials published in NEJM showed a 19 to 20% functional cure rate versus under 1% for standard of care, but the royalty flows through GSK’s commercialization and Ionis’s size mutes the stock impact. See the bepirovirsen primer.

5. INO-3107 (October 30, RRP). Inovio at $1.36 and a $140 million market cap. A recurrent respiratory papillomatosis approval would transform a $140 million company, but Inovio’s balance sheet and execution history keep it a speculative hold. See the INO-3107 RRP primer.

6. VNDA imsidolimab (December 12, GPP). Vanda at $5.34 and a $330 million market cap. Generalized pustular psoriasis is a small market and Vanda’s pipeline is thin, but a $330 million company with an approvable drug is the kind of name that doubles on a clean approval. See the imsidolimab primer.

7. MRK WELIREG+LENVIMA (October 4, RCC). Merck at $152.34 and a $374 billion market cap. The LITESPARK-011 PFS win is real, but for Merck this is immaterial. One sentence: the PDUFA passes and the stock does not move. See the WELIREG primer.

8. MRK I-DXd (October 10, SCLC). Same Merck. The first B7-H3 ADC in SCLC is a milestone for the field, not for Merck’s equity. Accelerated approval on single-arm data, immaterial to a $374 billion company. See the I-DXd SCLC PDUFA primer.

Year-end wildcard readouts

Three Q4 data drops can land any week and will not wait for a PDUFA date.

MIRM maralixibat (Q4, biliary atresia). Mirum at $100.63 and a $6.09 billion market cap. The EXPAND Phase 3 tests a label expansion beyond LIVMARLI’s approved indications. Positive data would de-risk a major pediatric liver franchise; a miss would hit a $6 billion multiple hard. See the maralixibat primer.

ADCT ZYNLONTA (Q4, r/r DLBCL). ADC Therapeutics at $1.32 and a $170 million market cap. The confirmatory DLBCL dataset is the catalyst, and a sub-$200 million company trading on a single-asset thesis is the definition of binary. See the ZYNLONTA primer.

NAMS obicetrapib (Q4, PREVAIL interim). NewAmsterdam at $25.85 and a $3.06 billion market cap. The CETP redemption story hinges on this interim. A clean cardiovascular outcome read would re-rate the stock; a null interim would send it back toward cash. See the obicetrapib note.

The sizing rules

The 1 to 2% per binary rule is not a suggestion in Q4; it is the difference between surviving a CRL and getting wiped out. December liquidity dries up, spreads widen, and stop-losses get run in thin holiday tape. Hold cash through the final two weeks and deploy into the washout names in the last week of December, when the forced sellers have already capitulated and the bid is gone. Sell the January-effect names in the first two weeks of January, which is historically when the rebound peaks and the tax-loss unwind runs its course. The full portfolio logic is in the guide to surviving CRLs.

What not to do

Do not buy biotech in late December with money you need in January. The liquidity is gone, the spreads are wide, and the tax-loss selling has not finished. Do not size a single binary above 2%. Do not treat a mega-cap PDUFA as a tradeable event; the Merck dates will not move the stock.

Verdict

The Q4 playbook in one sentence: buy the four washout names into late-December tax-loss selling, front-run BBIO and SVRA ahead of their November PDUFAs, and let the mega-cap Merck dates pass without touching them. The January effect is the closest thing biotech has to a free lunch, and the Q4 PDUFA calendar is the closest thing it has to a loaded gun. Position for both, and the biotech cycle does the rest.